Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Cancer Cell

Volumn 29, Issue 3, 2016, Pages 255-269

  Goel, Shom ^a   Wang, Qi ^a,j   Watt, April C ^a   Tolaney, Sara M ^a   Dillon, Deborah A ^b   Li, Wei ^a,c   Ramm, Susanne ^b,d   Palmer, Adam C ^b,e   Yuzugullu, Haluk ^a   Varadan, Vinay ^f   Tuck, David ^g,k   Harris, Lyndsay N ^h   Wong, Kwok Kin ^a   Liu, X Shirley ^a,c   Sicinski, Piotr ^a,b   Winer, Eric P ^a   Krop, Ian E ^a   Zhao, Jean J ^a,b,i  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k CURIS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; CARBOPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NAVELBINE; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; TUBERIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MORTALITY; NUDE MOUSE; PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84962921611     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.02.006     Document Type: Article

References (29)

1. Arteaga C.L., Engelman J.A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014, 25:282-303.
2. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
3. Bliss C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 1939, 26:585-615.
4. Carey L.A., Barry W.T., Pitcher B., Hoadley K.A., Cheang M.C., Anders C.K., Henry N.L., Tolaney S.M., Dang C.T., Krop I.E., et al. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). J. Clin. Oncol. 2014, 32:506.
5. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
6. Choi Y.J., Li X., Hydbring P., Sanda T., Stefano J., Christie A.L., Signoretti S., Look A.T., Kung A.L., von Boehmer H., Sicinski P. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012, 22:438-451.
7. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
8. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
9. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Development 1998, 12:3499-3511.
10. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos A.B., Rodon J., Ibrahim Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Translational Med. 2013, 5:196ra199.
11. Goodrich D.W., Wang N.P., Qian Y.W., Lee E.Y., Lee W.H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991, 67:293-302.
12. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
13. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66:1630-1639.
14. Lane H.A., Fernandez A., Lamb N.J., Thomas G. p70s6k function is essential for G1 progression. Nature 1993, 363:170-172.
15. Li A., Liu Z., Lezon-Geyda K., Sarkar S., Lannin D., Schulz V., Krop I., Winer E., Harris L., Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res. 2011, 39:4928-4941.
16. Moasser M.M., Krop I.E. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015, 1:1154-1161.
17. Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
18. Mukherjee S., Louie S.G., Campbell M., Esserman L., Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene 2000, 19:5982-5987.
19. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
20. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
21. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., Borgman C.L., Zaghlul S., Brandstetter K.A., Kubo S., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. USA 2009, 106:474-479.
22. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Development 2004, 18:2699-2711.
23. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
24. Tate S.C., Cai S., Ajamie R.T., Burke T., Beckmann R.P., Chan E.M., De Dios A., Wishart G.N., Gelbert L.M., Cronier D.M. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin. Cancer Res. 2014, 20:3763-3774.
25. Tolaney S.M., Rosen L.S., Beeram M., Goldman J.W., Gandhi L., Tolcher A.W., Papadopoulos K.P., Rasco D.W., Myrand S.P., Hulanthaviel P., et al. Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer. Cancer Res. 2015, 75. P5-19-13.
26. Vora S.R., Juric D., Kim N., Mino-Kenudson M., Huynh T., Costa C., Lockerman E.L., Pollack S.F., Liu M., Li X., et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014, 26:136-149.
27. Wang Q., Liu P., Spangle J.M., Von T., Roberts T.M., Lin N.U., Krop I.E., Winer E.P., Zhao J.J. PI3K-p110alpha mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 2015, 10.1038/onc.2015.406.
28. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
29. Zacharek S.J., Xiong Y., Shumway S.D. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 2005, 65:11354-11360.